Abstract
Objective. To assess the dose prescription patterns for risperidone long-acting injectable (RLAI) in patients with schizophrenia who participated in the 6-month, open-label Switch to Risperidone Microspheres (StoRMi) trial. Methods. Clinically stable patients requiring a change in medication were converted to RLAI prescribed using clinically-appropriate doses, as determined by treating clinicians. RLAI 25 mg was recommended as the starting dose, although higher initiation doses were permitted if deemed necessary. RLAI was administered intramuscularly every 2 weeks, with dosage adjustments permitted, and continued for a total of 6 months. Efficacy outcomes included Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity (CGI-S). Treatment-emergent adverse events (AEs) were monitored. Results. A total of 1,849 patients were included. Modal dose was 25 mg for 52.9% of patients. At baseline, patients treated with lower RLAI doses were more likely to be female, have shorter disease duration, milder symptoms, and be using less polypharmacy. The strongest predictors that a patient would remain on 25 mg RLAI were baseline PANSS hallucinatory behaviour item score (odds ratio [OR]=0.78), baseline CGI-S score (OR=0.69), female gender (OR=1.56), and country of residence (P
| Original language | English |
|---|---|
| Pages (from-to) | 36-47 |
| Number of pages | 12 |
| Journal | International Journal of Psychiatry in Clinical Practice |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Mar 2009 |
Fingerprint
Keywords
- Antipsychotic
- Injectable
- Long-acting
- Risperidone
- Schizophrenia
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
Dosing patterns in Europe : Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg. / Mauri, Massimo Carlo; Turner, Martin; Volonteri, Lucia S.; Medori, Rossella; Maier, Wolfgang.
In: International Journal of Psychiatry in Clinical Practice, Vol. 13, No. 1, 03.2009, p. 36-47.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dosing patterns in Europe
T2 - Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg
AU - Mauri, Massimo Carlo
AU - Turner, Martin
AU - Volonteri, Lucia S.
AU - Medori, Rossella
AU - Maier, Wolfgang
PY - 2009/3
Y1 - 2009/3
N2 - Objective. To assess the dose prescription patterns for risperidone long-acting injectable (RLAI) in patients with schizophrenia who participated in the 6-month, open-label Switch to Risperidone Microspheres (StoRMi) trial. Methods. Clinically stable patients requiring a change in medication were converted to RLAI prescribed using clinically-appropriate doses, as determined by treating clinicians. RLAI 25 mg was recommended as the starting dose, although higher initiation doses were permitted if deemed necessary. RLAI was administered intramuscularly every 2 weeks, with dosage adjustments permitted, and continued for a total of 6 months. Efficacy outcomes included Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity (CGI-S). Treatment-emergent adverse events (AEs) were monitored. Results. A total of 1,849 patients were included. Modal dose was 25 mg for 52.9% of patients. At baseline, patients treated with lower RLAI doses were more likely to be female, have shorter disease duration, milder symptoms, and be using less polypharmacy. The strongest predictors that a patient would remain on 25 mg RLAI were baseline PANSS hallucinatory behaviour item score (odds ratio [OR]=0.78), baseline CGI-S score (OR=0.69), female gender (OR=1.56), and country of residence (P
AB - Objective. To assess the dose prescription patterns for risperidone long-acting injectable (RLAI) in patients with schizophrenia who participated in the 6-month, open-label Switch to Risperidone Microspheres (StoRMi) trial. Methods. Clinically stable patients requiring a change in medication were converted to RLAI prescribed using clinically-appropriate doses, as determined by treating clinicians. RLAI 25 mg was recommended as the starting dose, although higher initiation doses were permitted if deemed necessary. RLAI was administered intramuscularly every 2 weeks, with dosage adjustments permitted, and continued for a total of 6 months. Efficacy outcomes included Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity (CGI-S). Treatment-emergent adverse events (AEs) were monitored. Results. A total of 1,849 patients were included. Modal dose was 25 mg for 52.9% of patients. At baseline, patients treated with lower RLAI doses were more likely to be female, have shorter disease duration, milder symptoms, and be using less polypharmacy. The strongest predictors that a patient would remain on 25 mg RLAI were baseline PANSS hallucinatory behaviour item score (odds ratio [OR]=0.78), baseline CGI-S score (OR=0.69), female gender (OR=1.56), and country of residence (P
KW - Antipsychotic
KW - Injectable
KW - Long-acting
KW - Risperidone
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=60749131650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60749131650&partnerID=8YFLogxK
U2 - 10.1080/13651500802411979
DO - 10.1080/13651500802411979
M3 - Article
AN - SCOPUS:60749131650
VL - 13
SP - 36
EP - 47
JO - International Journal of Psychiatry in Clinical Practice
JF - International Journal of Psychiatry in Clinical Practice
SN - 1365-1501
IS - 1
ER -